The Effect of Dapagliflozin on Platelet Function Testing Profiles in Diabetic Patients: The EDGE Pilot Study

Introduction This prospective pharmacodynamic (PD) study assessed the effect of the sodium-glucose co-transporter-2 inhibitor (SGLT2i), dapagliflozin, on platelet reactivity. Methods Patients with stable coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) ( n  = 27) who were on mainten...

Full description

Saved in:
Bibliographic Details
Published in:Cardiology and Therapy 2021-12, Vol.10 (2), p.561-568
Main Authors: Seecheran, Naveen, Grimaldos, Kathryn, Ali, Kabeer, Grimaldos, Gabriella, Richard, Srivane, Ishmael, Aleena, Gomes, Ceylon, Karan, Abhinav, Seecheran, Rajeev, Seecheran, Valmiki, Persad, Sangeeta, Abdullah, Harun, Peram, Lakshmipathi, Dookeeram, Darren, Giddings, Stanley, Motilal, Shastri, Raza, Sadi, Tello-Montoliu, Antonio, Schneider, David
Format: Article
Language:English
Subjects:
Activation
Blood platelets
Cardiology
Coronary heart disease
Dapagliflozin
Drug therapy
Internal Medicine
Medicine
Medicine & Public Health
NCT
NCT04400760
Original Research
Patient outcomes
Pharmacology, Experimental
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction This prospective pharmacodynamic (PD) study assessed the effect of the sodium-glucose co-transporter-2 inhibitor (SGLT2i), dapagliflozin, on platelet reactivity. Methods Patients with stable coronary artery disease (CAD) and type 2 diabetes mellitus (T2DM) ( n  = 27) who were on maintenance dual antiplatelet therapy (DAPT) of aspirin 81 mg daily, and clopidogrel 75 mg daily were recruited. Platelet function was evaluated with the VerifyNow™ P2Y 12 assay (Werfen, Bedford, MA, USA) and assessed prior to initiation of and after 10 days of treatment with dapagliflozin 10 mg once-daily dose regimen. Results were compared with a paired t  test. Results Treatment with dapagliflozin significantly decreased P2Y12 reaction units (PRU) by 20%, (95% confidence interval (CI) 8.5–32.6%, p value 0.002). The mean difference in PRU was 36.70 (95% CI 16.66–56.75). No patients experienced any serious adverse events (SAEs). Conclusions Significantly diminished platelet reactivity was observed on dapagliflozin as compared to without dapagliflozin. This dedicated pharmacodynamic study could be potentially informative and applicable for Trinidadian stable CAD patients with T2DM on DAPT. Further studies are required to confirm these exploratory findings. Clinical Trial Registration EDGE ClinicalTrials.gov number NCT04400760.
ISSN:2193-8261
2193-6544
DOI:10.1007/s40119-021-00242-6